Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that it has closed on the Company's previously announced strategic partnership agreement with Oramed Pharmaceuticals Inc. (NASDAQ:ORMP).

The transaction has positioned Lifeward as a diversified biomedical innovation company with an expected clear path to profitability. Lifeward acquired Oramed's clinical-stage Protein Oral Delivery (POD™) technology, adding exposure to a large, long-term biotech market opportunity. Through the new partnership, Lifeward has access to up to $47 million of capital from Oramed and certain investors, and on March 25, 2026 Lifeward accessed $10 million of such capital. The Company has also made changes to its board of directors. More information about the closing of the transaction may be viewed in Lifeward's Form 8-K filed on March 25, 2026.